Results 91 to 100 of about 15,628 (311)

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy

European Journal of Haematology, Volume 116, Issue 2, Page 104-115, February 2026.
ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley   +1 more source

Limitations of FAERS‐based analyses of paternal drug exposure: The critical need for maternal data integration

Andrology, EarlyView.
Mikako Goto, Izumi Fujioka, Yasuha Ogawa, Sachi Koinuma, Koushi Yamaguchi   +4 more
wiley   +1 more source

Multidimensional Assessment of Neurological Adverse Reactions Related to PD‐1 Inhibitors: A Real‐World Pharmacovigilance Study

CNS Neuroscience &Therapeutics, Volume 32, Issue 1, January 2026.
This pharmacovigilance study systematically analyzed PD‐1 inhibitor–associated neurological adverse events using FAERS data from 2014 to 2024. Central nervous system toxicities, including encephalitis and brainstem encephalitis, were most prominent. Older age, female sex, specific cancer types, and combination therapies increased the risk, with most ...
Xiaofeng Hu, Xiaoli Wang, Bufu Tang, Dehuan Zhang, Rongbing Cai, Hui Jiang, Yaling Lin, Yiheng Song, Yiou Wang, Hairuo Huang, Dandan Guo, Xubin Sun, Hongjie Fan   +12 more
wiley   +1 more source

Expanding on Abraxane Safety: Temporal Insights and Future Directions for Adverse Event Analysis [Letter]

International Journal of Nanomedicine
Fangcai Yang,1 Wukun Ge2 1Department of Clinical Nutrition, Ninghai First Hospital, Ningbo, Zhejiang, 315600, People’s Republic of China; 2Department of Clinical Pharmacy, Ninghai First Hospital, Ningbo, Zhejiang, 315600, People’s Republic of
Yang F, Ge W
doaj  

Phase diagram for a mixture of colloids and polymers with equal size [PDF]

, 2008
We present the phase diagram of a colloid-polymer mixture in which the radius a of the colloidal spheres is approximately the same as the radius R of a polymer coil (q=R/a1).
Aarts, D.G.A.L., Colloïden en grenslagen, Dep Scheikunde, Egelhaaf, S.U., Fleer, G.J., Lekkerkerker, H.N.W., Poon, W.C.K., Smith, P.A., Tuinier, R.   +8 more
core   +2 more sources

Pharmacovigilance Insights Into Immune Checkpoint Inhibitor‐Induced Risk of Paraneoplastic Syndrome: A Large‐Scale Real World Study

CNS Neuroscience &Therapeutics, Volume 32, Issue 1, January 2026.
Immune checkpoint inhibitors are associated with rare but severe paraneoplastic syndromes, particularly in lung cancer patients. PS onset shows a bimodal pattern, with increased severity seen in combination therapies like durvalumab plus tremelimumab.
Bufu Tang, Xin Song, Yiting Sun, Juncheng Wan, Wenlu Hu, Yifei Ma, Yihang Lin, Jian Zhang, Yiou Wang, Hongyang Feng, Peng Luo, Dandan Guo, Xudong Qu   +12 more
wiley   +1 more source

Gabapentinoids-Related Delirium Adverse Events: A Real-World Study from 2004 to 2022 Based on FAERS

Journal of Pain Research
Zhongbiao Nie,1 Cuilv Liang,2 Zhihong Li,1 Xinqiang Han,3 Ran Zhang4 1Department of Pharmacy, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, People’s ...
Nie Z, Liang C, Li Z, Han X, Zhang R
doaj  

Dupilumab and the potential risk of eosinophilic pneumonia: case report, literature review, and FAERS database analysis

Frontiers in Immunology
Eosinophilic pneumonia (EP) is a rare but noteworthy adverse effect linked to dupilumab, an interleukin-4 (IL-4) and IL-13 inhibitor used in the managing atopic diseases. The underlying mechanisms, potential predisposing factors, clinical characteristics,
Xiyuan Zhou, Ge Yang, Xuemei Zeng, Lan Wang, Jing Xiang, Jinyu Zhao, Xuejun Chen, Lixia Zhang   +7 more
semanticscholar   +1 more source

Quantitative Systems Toxicology Predicts Ivacaftor‐Induced Oxidative Stress Contributes to CFTR Modulator Hepatotoxicity

Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 208-218, January 2026.
Cystic fibrosis (CF) is a chronic hereditary disease that affects tens of thousands of people worldwide. The introduction of CFTR modulator therapies such as elexacaftor/tezacaftor/ivacaftor (ETI) has significantly improved the quality of life of people with CF.
Alan Shi, Cole Cornwell, Kyunghee Yang, Paul M. Beringer   +3 more
wiley   +1 more source

Disproportionality analysis of interstitial lung disease associated with novel antineoplastic agents during breast cancer treatment: a pharmacovigilance studyResearch in context

EClinicalMedicine
Summary: Background: Studies have shown that some antineoplastic agents may be associated with interstitial lung disease (ILD), but large-scale real-world data are lacking.
Zijun Zhu, Yongxin Li, Chaoyong Zhu, Qiuxia Dong, Yixiao Zhang, Zhilin Liu, Dengfeng Ren, Fuxing Zhao, Jiuda Zhao   +8 more
doaj   +1 more source